Status:
COMPLETED
Vascular Access for Hemodialysis and Inflammation
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
Vascular Access for Hemodialysis and Inflammation
Eligibility:
All Genders
18-85 years
Brief Summary
The aim of the present study was to investigate patients free of active infection and/or thrombosis to assess if the type of vascular access (AVF, AVG, TCC), could influence: 1. the levels of serolog...
Detailed Description
Patients with AVF assumed ticlopidine 250 mg/die, patients with TCC and AVG assumed warfarin to maintain target INR between 1.8 and 2.5. Six wash out consecutive sessions were carried out before star...
Eligibility Criteria
Inclusion
- All the patients recruited for the study were infection and thrombosis free from almost 6 months.
- No patients included had autoimmune disease, hepatic failure, diabetes or malignancy.
- Patients were not administered ACE inhibitors, angiotensin receptor antagonists, antiinflammatory or immunosuppressive drugs.
- All the patients had residual GFR \< 5 ml/min.
- The vascular access considered were placed from at least 6 months.
Exclusion
- Patients with recirculating vascular access \> 10% were excluded from the study.
- Patients with acute cardiovascular accident in the last 15 days before starting the study.
Key Trial Info
Start Date :
January 1 2000
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
458 Patients enrolled
Trial Details
Trial ID
NCT00850707
Start Date
January 1 2000
End Date
December 1 2008
Last Update
March 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nephrology Dialysis Transplantation Unit St.Orsola University Hospital
Bologna, Italy, 40138